Curcumin inhibits the classical and the alternate pathways of complement activation

Amod P. Kulkarni, Yohannes T. Ghebremariam, Girish J. Kotwal

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Curcumin (Cur), the golden yellow phenolic compound in turmeric, is well studied for its medicinal properties. In the current investigation, Cur dissolved using sodium hydroxide solution (CurNa) was tested for in vitro complement inhibitory activity and compared with rosmarinic acid (RA) and quercetin (Qur) dissolved using sodium hydroxide (RANa and QurNa, respectively) and the vaccinia virus complement control protein (VCP). The comparative study indicated that CurNa inhibited the classical complement pathway dose dependently (IC50 = 404 μM). CurNa was more active than RANa, but less active than QurNa. VCP was about 2,212, 2,786, and 4,520 times more active than QurNa, CurNa, and RANa, respectively. Further study revealed that CurNa dose dependently inhibited zymosan-induced activation of the alternate pathway of complement activation.

Original languageEnglish (US)
Pages (from-to)100-112
Number of pages13
JournalAnnals of the New York Academy of Sciences
StatePublished - 2005


  • Alternate pathway (AP)
  • Bb
  • C3b
  • Classical pathway (CP)
  • Complement
  • Curcumin
  • Hemolysis
  • Quercetin
  • Rosmarinic acid
  • VCP

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Curcumin inhibits the classical and the alternate pathways of complement activation'. Together they form a unique fingerprint.

Cite this